Substance / Medication

Thalidomide

Overview

Active Ingredient
thalidomide
RxNorm CUI
10432
Labeler: Celgene CorporationUpdated: 2023-03-24T00:00:00.000ZFull label on DailyMed

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

Clinical Trials

3 trials linked to this intervention

3
Total Trials
3
Recruiting
0
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Efficacy and safety of thalidomide for oncology-related uses approved in Brazil: An overview of systematic reviews.
de Miranda Drummond Paula Lana, de Araújo Silva Cristine, de Souza Júlia Estevão et al. · J Oncol Pharm Pract · 2025
PMID: 40530461Meta-Analysis
Safety and efficacy of thalidomide in treatment of gastrointestinal bleeding secondary to angioectasias: a systematic review and meta-analysis.
Singh Sahib, Mohan Babu P, Sanaei Omid et al. · Scand J Gastroenterol · 2024
PMID: 38629130Meta-Analysis
Lenalidomide or Thalidomide for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma? An Overview of Systematic Reviews.
Visacri Marília Berlofa, Ribeiro Mayra Carvalho, Komoda Denis Satoshi et al. · Value Health Reg Issues · 2024
PMID: 38718736Meta-Analysis
Effectiveness of thalidomide for ankylosing spondylitis: a meta-analysis of randomized controlled trials in China.
Wang Dongsen, Hu Xuemei, Yin Xuan et al. · Clin Rheumatol · 2022
PMID: 35635651Meta-Analysis
Efficacy and Safety of Thalidomide in Patients with Complicated Central Nervous System Tuberculosis: A Systematic Review and Meta-Analysis.
Panda Prateek Kumar, Panda Pragnya, Dawman Lesa et al. · Am J Trop Med Hyg · 2021
PMID: 34314371Meta-AnalysisFull text (PMC)
Thalidomide as a treatment for inflammatory bowel disease in children and adolescents: A systematic review.
Qiu Tingting, Li Huibo, Sun Tong et al. · J Clin Pharm Ther · 2020
PMID: 32743898Meta-Analysis

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Specialists

Providers who commonly manage this intervention

Health Goals

Goals connected through associated conditions

Quick Facts

Type
Substance / Medication
Fully Specified Name
Thalidomide (substance)
SNOMED CT
78702007
UMLS CUI
C0039736
RxNorm CUI
10432
Labeler
Celgene Corporation

Clinical Data

This intervention maps to 19 entities in the Healos knowledge graph.

14
Conditions
2
Biomarkers
1
Specialists
0
Symptoms
3
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.